Adam M. Wexner

Adam M. Wexner, P.C. — Kirkland & Ellis (Chicago)

Background

• Corporate/M&A partner; core practice is representing PE sponsors and portfolio companies, with a strong recurring healthcare and pharma-services thread.
• Repeat outside counsel to EW Healthcare Partners and Curewell Capital, two healthcare-focused PE platforms active in CDMO and specialty pharma.
• Deal range from sub-$30M add-ons to $4B+ transactions — sees both the small bolt-on and platform-scale ends of the market.

Current focus

• Active on Curewell Capital's CDMO/API manufacturing investment thesis (Wilmington PharmaTech, Oct 2025).
• Historically deep on cell & gene therapy CDMO (Cognate BioServices/Charles River) and specialty/rare-disease pharma asset deals (EUSA Pharma/Sylvant).

What he cares about

• Deal execution certainty and structuring for PE sponsors, not target-side advisory.
• Long-term client relationships (same sponsors reappear across his deal list) — values repeat mandates over one-off transactions.

Recent moves

• October 2025: advised Curewell Capital on its investment in Wilmington PharmaTech, a small-molecule API CDMO — signals continued sponsor appetite for CDMO platforms.

Sensitivities

• As deal counsel, he is bound by client privilege/confidentiality — expect him to speak in generalities about market dynamics rather than specific unannounced deals.
• Any conversation should be framed as market color/relationship-building, not solicitation of confidential client information.

Questions to ask

1. What's driving sponsor demand for API/small-molecule CDMO platforms like Wilmington PharmaTech right now, and where do you see the next wave of consolidation?
2. Across the EW Healthcare and Curewell mandates, what deal terms or structures have become sticking points in current CDMO/pharma-services diligence?
3. Which sub-sectors of pharma services (cell & gene therapy, API manufacturing, specialty fill-finish) are you seeing the most inbound sponsor interest in today?